The miR-29b Byproduct MIRTX Shows Superior Anti-tumor Activity, Compared to miR-29b-3p, in Pancreatic Cancer Cells
{{output}}
Background/aim: Pancreatic cancer has a poor prognosis, with a 5-year survival rate of only 9%. Thus, there is an urgent need to develop effective cancer therapeutics for this disease. It is expected that nucleic acid therapeutic... ...